GlassScriptPhysician profile
Kiera Lyn Booth
NPI 1184006835
$49,723.24
in general payments reported to CMS, 2019-2025
37 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $553 · 2021: $742 · 2022: $2,350 · 2023: $2,248 · 2024: $3,426 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,047 · Travel and Lodging: $2,702 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,240.00 |
| Food and Beverage | $10,956.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,047.20 |
| Travel and Lodging | $2,702.40 |
| Education | $255.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $13,746.98 | 2020-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $11,071.58 | 2020-2025 | |
| Incyte Corporation | $6,658.48 | 2021-2025 | Opzelura |
| Eli Lilly and Company | $5,474.74 | 2025 | Ebglyss |
| Janssen Biotech, INC. | $2,173.96 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,975.08 | 2019-2025 | Skyrizi, Rinvoq |
| Organon LLC | $951.06 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $897.70 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $774.19 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $772.70 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $706.25 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $661.98 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Lilly USA, LLC | $620.99 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $534.99 | 2020-2025 | Aklief, Nemluvio, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $474.03 | 2019-2025 | Siliq, Arazlo, Cabtreo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $470.89 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $285.95 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.46 | 2022-2025 | Spevigo |
| Genzyme Corporation | $254.28 | 2021-2025 | |
| Dermavant Sciences, INC. | $218.15 | 2023-2024 | Vtama |
| Almirall LLC | $118.94 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $87.61 | 2019 | |
| Vyne Pharmaceuticals INC. | $65.66 | 2021 | |
| Mallinckrodt Hospital Products INC. | $64.43 | 2024 | Acthar |
| Journey Medical Corporation | $59.75 | 2022 | |
| Dermira, INC. | $58.75 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Botanix Sb INC | $25.38 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $22.35 | 2025 | Nuzyra |
| Biofrontera INC. | $20.02 | 2022 | |
| Smith+Nephew, INC. | $16.57 | 2023 | Regranex, Collagenase Santyl |
| Kyowa Kirin, INC. | $16.31 | 2024 | Poteligeo |
| Strata Skin Sciences, INC. | $15.25 | 2025 | Xtrac |
| Epi Health, LLC | $15.24 | 2022 | |
| Mayne Pharma Commercial LLC | $14.19 | 2020 | |
| Fresenius Kabi USA, LLC | $12.85 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiera Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.